Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes
Anticipated Profits From Biosimilar Candidates To Expand Future Development
Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.
You may also be interested in...
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.
Siggi Olafsson has taken the reins at Mallinckrodt after stepping down as Hikma’s CEO. At the same time, Teva has named a new global R&D and chief medical officer while Piramal Pharma Solutions has appointed a fresh COO and Formycon has added to its supervisory board.
Formycon has seen its FYB201 ranibizumab biosimilar rival to Lucentis recommended for approval by the EMA’s CHMP, under the name Ranivisio. Teva has rights to market the product in Europe and is preparing for launch.